Sign Up to like & get
recommendations!
1
Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.7590
Abstract: Background Gout is the most common inflammatory arthritis in humans; is caused by deposition of monosodium urate (MSU) crystals within and around joints. Left untreated, a more chronic course may develop, characterised by persistent inflammation…
read more here.
Keywords:
low dose;
dose anti;
therapy;
gout ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Diabetes Care"
DOI: 10.2337/dc18-0494
Abstract: OBJECTIVE A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized…
read more here.
Keywords:
low dose;
dose atg;
dose anti;
atg ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.902254
Abstract: A small dose of the anti-HIV drug efavirenz (EFV) was previously discovered to activate CYP46A1, a cholesterol-eliminating enzyme in the brain, and mitigate some of the manifestation of Alzheimer’s disease in 5XFAD mice. Herein, we…
read more here.
Keywords:
alzheimer disease;
dose anti;
retinal vascular;
vascular lesions ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "International journal of clinical pharmacology and therapeutics"
DOI: 10.5414/cp203640
Abstract: OBJECTIVE Low-molecular-weight heparins are frequently used to prevent venous thromboembolism. Vasopressor therapy may be associated with inadequate anti-factor Xa activity, thereby increasing the risk of venous thromboembolism. We aimed to assess the association between anti-factor…
read more here.
Keywords:
activity;
norepinephrine dose;
factor;
dose anti ... See more keywords